{
    "clinical_study": {
        "@rank": "141181", 
        "acronym": "HELPuc", 
        "arm_group": {
            "arm_group_label": "H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)", 
            "arm_group_type": "Experimental", 
            "description": "A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, single center clinical investigation to evaluate the efficacy and\n      safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a\n      treatment for non-exudative (dry) Age-related Macular Degeneration (AMD). A total of 14\n      clinic visits are scheduled, one baseline visit, 8 visits for H.E.L.P. therapy treatments\n      (to be performed over a period of 12 weeks for each patient) and 5 follow-up visits to be\n      performed one week following the 4th H.E.L.P. therapy session and 12 weeks, 24 weeks, 36\n      weeks and 52 weeks after the final H.E.L.P. therapy session."
        }, 
        "brief_title": "HELP Therapy for Dry AMD", 
        "condition": "Non-exudative (Dry) Age-related Macular Degeneration (AMD)", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of non-exudative (dry) AMD\n\n          -  Male or female, between 50 and 90 years\n\n          -  Presence of soft, confluent drusen in study eye\n\n          -  At least one large (>125 \u03bcm) drusen\n\n          -  Visual acuity (VA) between 20/32 and 20/100 Early treatment Diabetic Retinopathy\n             Study (ETDRS) vision\n\n          -  Fibrinogen level >100mg/dL\n\n          -  Willing to continue lipid-lowering medication throughout the treatment phase if such\n             medication was taken already before the study\n\n          -  Willing to continue regular supplemental intake of Age related Eye Disease Study\n             (AREDS) vitamins or comparable supplements throughout the study course\n\n          -  Written informed consent\n\n        Exclusion Criteria (related to the underlying disease):\n\n          -  Any evidence of wet AMD in either eye\n\n          -  History of treatment for wet AMD in either eye\n\n          -  Geographic atrophy involving fovea in study eye\n\n          -  Fellow eye <20/400 VA\n\n          -  Presence of cataract requiring treatment during study\n\n          -  Presence of glaucoma requiring new treatment during study\n\n          -  Presence of diabetic or other vascular retinopathy\n\n          -  Previous retinal laser or surgical therapy\n\n          -  Epiretinal membrane in study eye\n\n          -  Any other ocular condition requiring therapy during the study\n\n        Exclusion Criteria (General):\n\n          -  Participation in another clinical trial within 30 days\n\n          -  Concurrent participation in another clinical trial\n\n          -  Pregnancy or lactation\n\n          -  Inability to give or understand informed consent\n\n          -  Inability to maintain treatment and follow-up schedule\n\n          -  Hypersensitivity to fluorescein\n\n          -  Test positive for infectious status from HIV-, HBV- and HCV- infection\n\n        Exclusion Criteria (H.E.L.P. Apheresis):\n\n          -  Heparin intolerance\n\n          -  Heparin induced thrombocytopenia (HIT) II\n\n          -  Hemorrhagic diathesis\n\n          -  Ulcers in the gastrointestinal area\n\n          -  Hemorrhage\n\n          -  Coagulation disorder and neoplasm\n\n          -  Liver diseases\n\n          -  Severe heart failure and valvular defect\n\n          -  Condition following apoplexia\n\n          -  Dementia\n\n          -  During pregnancy and lactation\n\n          -  C1 esterase inhibitor deficiency or hereditary complement component 3 (C3) deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840683", 
            "org_study_id": "BA-I-H-1202"
        }, 
        "intervention": {
            "arm_group_label": "H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)", 
            "intervention_name": "H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)", 
            "intervention_type": "Device", 
            "other_name": "Heparin-Induced Extracorporeal LDL-Cholesterol Precipitation"
        }, 
        "intervention_browse": {
            "mesh_term": "Heparin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Age-Related Macular Degeneration (AMD)", 
            "Age Related Eye Disease Study (AREDS)", 
            "Best-Corrected Visual Acuity (BCVA)", 
            "Early Treatment Diabetic Retinopathy Study (ETDRS)", 
            "Heparin-Induced Extracorporeal LDL-Cholesterol Precipitation (HELP)", 
            "Visual Function Questionnaire (VFQ)"
        ], 
        "lastchanged_date": "May 6, 2013", 
        "location": {
            "contact": {
                "email": "research@retinamd.ca", 
                "last_name": "Fareed Ali, MD, FRCS(C)", 
                "phone": "1-905-212-9482", 
                "phone_ext": "234"
            }, 
            "contact_backup": {
                "email": "nancy.davis@retinamd.ca", 
                "last_name": "Narendra Armogan, MD, FRCS(C)", 
                "phone": "1-905-212-9482", 
                "phone_ext": "234"
            }, 
            "facility": {
                "address": {
                    "city": "Mississauga", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L4W 1W9"
                }, 
                "name": "Canadian Centre for Advanced Eye Therapeutics Inc."
            }, 
            "investigator": [
                {
                    "last_name": "Fareed Ali, MD, FRCS(C)", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Narendra Armogan, MD, FRCS(C)", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Single Center Study to Evaluate the Efficacy and Safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a Treatment for Non-exudative (Dry) Age-related Macular Degeneration (AMD)", 
        "overall_contact": {
            "email": "research@retinamd.ca", 
            "last_name": "Fareed Ali, MD, FRCS(C)", 
            "phone": "+1-905-212-9482"
        }, 
        "overall_contact_backup": {
            "email": "nancy.davis@retinamd.ca", 
            "last_name": "Narendra Armogan, MD, FRCS(C)", 
            "phone": "+1-905-212-9482", 
            "phone_ext": "234"
        }, 
        "overall_official": {
            "affiliation": "Canadian Centre for Advanced Eye Therapeutics Inc.", 
            "last_name": "Fareed Ali, MD, FRCS(C)", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA) in patients with non-exudative (dry) AMD.", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline in the best corrected visual acuity (BCVA) at Week 24 after completion of H.E.L.P. therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840683"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate the effects of H.E.L.P. therapy on the change in drusen area as assessed by colour photography.", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy"
            }, 
            {
                "measure": "To evaluate the effects of H.E.L.P. therapy in area of abnormal autofluorescence as assessed by Fundus Autofluorescence (FAF).", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy"
            }, 
            {
                "measure": "To evaluate the effects of H.E.L.P. therapy on overall visual functioning as assessed by the Visual Functioning Questionnaire (VFQ)-25 test.", 
                "safety_issue": "No", 
                "time_frame": "Change from Baselineto Weeks 24 and 52 after completion of H.E.L.P. therapy"
            }, 
            {
                "measure": "To evaluate the safety of H.E.L.P. therapy by assessing laboratory tests and vital signs.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and at all HELP therapy sessions being conducted after Baseline within 12 weeks."
            }, 
            {
                "measure": "To evaluate the effects of H.E.L.P. on the integrity of the outer retinal bands as assessed by Optical Coherence Tomography (OCT)", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in integrity of the outer retinal bands at Weeks 24 and 52 after completion of H.E.L.P. therapy"
            }, 
            {
                "measure": "To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA).", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Week 52 after completion of H.E.L.P. therapy"
            }, 
            {
                "measure": "To evaluate the effects of H.E.L.P. therapy on the AREDS severity scale as assessed by colour photography.", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy"
            }, 
            {
                "measure": "To evaluate the effects of H.E.L.P. therapy on the incidence and change in area of geographic hypo autofluorescence as assessed by fundus autofluorescence images.", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy"
            }, 
            {
                "measure": "To evaluate the effects of H.E.L.P. on the drusen volume as assessed by Optical Coherence Tomography (OCT)", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy"
            }, 
            {
                "measure": "To evaluate the safety of H.E.L.P. therapy by assessing adverse events (AEs).", 
                "safety_issue": "Yes", 
                "time_frame": "At all H.E.L.P. therapy sessions and follow-up visits being conducted after Baseline within 12 weeks and 12, 24, 36 and 52 weeks after completion of the H.E.L.P. therapy."
            }, 
            {
                "measure": "To evaluate the safety of H.E.L.P. therapy by physical examination.", 
                "safety_issue": "Yes", 
                "time_frame": "At all H.E.L.P. therapy sessions being conducted after Baseline within 12 weeks and 52 weeks after completion of the H.E.L.P. therapy."
            }
        ], 
        "source": "B.Braun Avitum AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "B.Braun Avitum AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}